Market News & Trends
Enteris BioPharma Initiates Feasibility Program With Ferring Pharmaceuticals to Develop Oral Formulation of a Peptide
Enteris BioPharma, Inc. recently announced it has entered into a feasibility development agreement with Ferring Pharmaceuticals to utilize Enteris' proprietary oral delivery platform, Peptelligence, to…
International Stem Cell Corporation Completes Dosing of Second Cohort in Parkinson's Disease Trial
International Stem Cell Corporation recently announced the eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson's disease, was…
Ginolis Provides Mobidiag High Throughput Manufacturing Lines for Growing Needs of Novodiag Cartridges
Ginolis Ltd recently announced it has signed an agreement with Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company. Through the implementation of cutting-edge…
Grand River Aseptic Manufacturing Continues to Expand Capabilities With New, State-of-the-Art Colanar Syringe Filler
Grand River Aseptic Manufacturing, Inc. (GRAM), a leading parenteral contract manufacturing organization, expands its capabilities in syringe filling at its FDA-inspected, cGMP-compliant manufacturing facility in…
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain Wilms Tumor 1 (WT1) peptides.
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018 utilizing JOT’s platform product,JOTROL.
Majority of Clinical Trials Planned in 2018 Belong to Oncology
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy areafor clinical trialsplanned to be initiated in 2018…
Evotec & Sanofi to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
BC Platforms Launches End-to-End Solution for Precision Medicine Powered by the Microsoft Genomics Service
BC Platforms, a pioneer in genomic data management and analytics, recently announced it has launchedGeneVision, a new end-to-end Solution for Precision Medicine, that uses theMicrosoft Genomics service which runs on Microsoft Azure.
Vividion Therapeutics Announces Strategic Research Collaboration With Celgene; $101 Million Up-Front Payment
Vividion Therapeutics, Inc., a biotechnology company using revolutionary proteomics and chemistry platforms,recently announced a strategic research collaboration with Celgene Corporation. The multi-year collaboration is focused…
Aduro Announces Development Milestone Achieved Under Merck Collaboration
Aduro Biotech, Inc. recently announced that the company earned a $3-million development milestone payment under its worldwide licensing agreement with Merck…
ProJect Pharmaceutics Expands Facilities for Formulation & Lyophilization Process Development
ProJect Pharmaceutics(PJP), specialized in formulation and process development for parenteral drug products, announces that it has extended its safety facilities by laboratories dedicated to handle GMO S2 and BSL-2 based biological products such as live virus vaccines…
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics companyGlobalData.
Catalent Completes Multi-Million Expansion at Singapore Clinical Supply Facility
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the completion of a two-year, $4.6 million…
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain…
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be…
Majority of Clinical Trials Planned in 2018 Belong to Oncology
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy area…
Enteris BioPharma Initiates Feasibility Program With Ferring Pharmaceuticals to Develop Oral Formulation of a Peptide
Enteris BioPharma, Inc. recently announced it has entered into a feasibility development agreement with Ferring Pharmaceuticals to utilize Enteris' proprietary oral delivery platform, Peptelligence, to…
International Stem Cell Corporation Completes Dosing of Second Cohort in Parkinson's Disease Trial
International Stem Cell Corporation recently announced the eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson's disease, was…
Ginolis Provides Mobidiag High Throughput Manufacturing Lines for Growing Needs of Novodiag Cartridges
Ginolis Ltd recently announced it has signed an agreement with Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company. Through the implementation of cutting-edge…
